Browsed by
Tag: Capabilities

MathWorks Enhances Rapid Control Prototyping and Hardware-in-the-Loop Testing Capabilities with QNX Neutrino Realtime Operating System (RTOS)

MathWorks Enhances Rapid Control Prototyping and Hardware-in-the-Loop Testing Capabilities with QNX Neutrino Realtime Operating System (RTOS)

MathWorks today announced key updates to Simulink Real-Time that enhance rapid control prototyping and hardware-in-the-loop (HIL) testing with Model-Based Design. In Release 2020b, Simulink Real-Time has been enabled with the QNX Neutrino RTOS, a multi-process 64-bit POSIX-compliant real-time operating system from BlackBerry. The QNX RTOS is widely used in life and safety-critical systems for vehicles, medical devices, industrial controls, rail, robotics and aerospace & defense.

The update builds on the existing Simulink Real-Time and Speedgoat integration, enabling engineers to extend their Simulink models with I/O driver blocks, automatically build real-time applications, create instrumentation, and perform interactive or automated runs on a target computer. Engineers can replace a physical system such as a vehicle, aircraft, or robot with a real-time simulation of a virtual system to reduce the cost of testing. The QNX Neutrino RTOS enables new workflows, making real-time computing problems easier to solve, particularly when multiple tasks compete for a system’s resources.

“MathWorks is renowned for supporting engineers and scientists, who are increasingly seeking novel techniques to improve their designs through simulation and testing,” said Grant Courville, VP, products and strategy, BlackBerry QNX. “QNX is the RTOS of choice for mission-critical embedded systems, and countless engineers across a wide range of industries rely on MathWorks’ Simulink Real-Time for simulation and Model-Based Design. This integration will allow teams to work in their preferred environment and reap the benefits that the QNX Neutrino RTOS has to offer from design to deployment.”

“Engineers working on complex embedded systems are constantly looking for ways to improve real-time simulation and testing with Model-Based Design,” said Jay Abraham, manager – verification products, MathWorks. “With the enablement of the QNX Neutrino RTOS, they can now work with Simulink Real-Time to address design challenges that require streamlined solutions for rapid control prototyping and HIL testing.”

Read the rest
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation An

Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation An

  Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research
    Facility to Enhance Development of Next Generation Antibody Radiation
              Conjugates Leveraging Its Proprietary AWE Platform

PR Newswire

NEW YORK, Oct. 14, 2020

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE
AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of
its new research and development lab facility in New York City.  This new
research facility expands Actinium's internal R&D capabilities and will be
focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC
therapeutic combination strategies, and supporting AWE platform research
collaborations. Actinium's R&D efforts will employ a multidisciplinary
approach leveraging its team's expertise and experience in cancer cell
biology, radiochemistry, radiation sciences, immunology and oncology drug
development.  The proprietary AWE technology platform, protected by over one
hundred and twenty-five patents, is the foundation for Actinium's R&D and
exploits multiple different radioisotope payloads including the potent
alpha-emitter, Actinium-225.  

(PRNewsfoto/Actinium Pharmaceuticals, Inc.)

This new research facility will function under the guidance of Dr. Dale
Ludwig, Ph.D. the Company's Chief Scientific & Technology Officer, who has
over twenty-five years of oncology discovery research and development
experience, including supporting the development and launch of Erbitux®,
Cyramza^TM, Portrazza®, and Lartruvo^TM as well as the clinical advancement of
at least 10 additional therapeutic antibodies and Antibody Drug Conjugates
while at Eli Lilly and, previously, ImClone Systems Inc.  The research
facility will be managed and staffed by Ph.D. level scientists who will
contribute their respective expertise in areas of drug discovery, radiation
chemistry, and translational research to advance novel ARC programs and
investigations into combination therapeutic strategies.

"Our new research facility will allow us to significantly accelerate our
preclinical and clinical development of novel ARC programs and investigate
mechanistic ARC therapeutic combinations, which utilize our expertise in
radioimmunobiology, our AWE Technology Platform capabilities, 
Read the rest